Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Earnings for Oramed Pharmaceuticals Inc. (ORMP)
Earnings in 2022 (TTM): $-37,664,000
According to Oramed Pharmaceuticals Inc.'s latest financial reports the company's current earnings (TTM) are $-37,664,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Oramed Pharmaceuticals Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-37,664,000 | $-37,764,000 |
| 2021 | $-22,989,000 | $-22,238,000 |
| 2020 | $-11,511,000 | $-11,511,000 |
| 2019 | $-14,055,000 | $-14,355,000 |
| 2018 | $-12,727,000 | $-12,727,000 |
| 2017 | $-10,080,000 | $-10,480,000 |
| 2016 | $-9,629,000 | $-10,964,000 |
| 2015 | $-7,233,000 | $-7,232,000 |
| 2014 | $-5,692,000 | $-5,696,000 |
| 2013 | $-4,436,874 | $-4,231,812 |
| 2012 | $-3,254,260 | $-3,344,478 |
| 2011 | $-1,585,225 | $-1,561,245 |
| 2010 | $-2,962,405 | $-2,977,376 |
| 2009 | $-2,763,071 | $-2,760,474 |
| 2008 | $2.61 M | $-2,769,271 |
| 2007 | $-3,236,000 | $-3,236,000 |
| 2006 | $-414,576 | $-414,576 |
| 2005 | $-45,781 | $-45,781 |
| 2004 | $-720,000 | $-720,000 |
| 2003 | $-50,000 | $-50,000 |